- Dupixent® (dupilumab) demonstrated superiority over Xolair® (omalizumab) in the EVEREST Phase 4 trial for CRSwNP and asthma.
- Study results showed significant improvements in nasal polyp size reduction and smell identification for Dupixent (ticker: REGN).
- Dupixent exhibited comparable safety to Xolair, with lower serious adverse event rates.
In a landmark head-to-head Phase 4 study, Regeneron Pharmaceuticals (REGN, Financial) and Sanofi revealed that Dupixent® (dupilumab) significantly outperformed Xolair® (omalizumab) in treating chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. The EVEREST trial, involving 360 adult patients, is the first to directly compare these biologic treatments across all primary and secondary endpoints in this patient population.
Patients receiving Dupixent saw a 1.60-point greater reduction in nasal polyp size and an 8.0-point superior improvement in smell identification compared to those on Xolair. Additionally, Dupixent users experienced a 150 mL improvement in lung function and enhanced asthma control, with notable improvements visible as early as four weeks into treatment.
The safety profile of Dupixent was found to be in line with Xolair, with adverse events reported in 64% of Dupixent patients compared to 67% for Xolair. Serious adverse events occurred in 2% of Dupixent patients versus 4% for Xolair, reinforcing Dupixent's favorable safety profile.
This trial strengthens the positioning of Dupixent in the respiratory biologics space by establishing its efficacy not only in upper but also lower respiratory conditions, targeting IL-4 and IL-13 pathways. With these results, Dupixent is expected to further solidify its market presence against its competitors in the treatment of both CRSwNP and asthma.
